BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ison MG. Influenza prevention and treatment in transplant recipients and immunocompromised hosts. Influenza Other Respir Viruses 2013;7 Suppl 3:60-6. [PMID: 24215383 DOI: 10.1111/irv.12170] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Buchan CA. Transplant Tourism and the Traveling Transplant Recipient: Infection Mitigation and Treatment Strategies. In: Morris MI, Kotton CN, Wolfe C, editors. Emerging Transplant Infections. Cham: Springer International Publishing; 2020. pp. 1-39. [DOI: 10.1007/978-3-030-01751-4_12-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Haidar G, Mellors JW. Improving the Outcomes of Immunocompromised Patients with COVID-19. Clin Infect Dis 2021:ciab397. [PMID: 33949644 DOI: 10.1093/cid/ciab397] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
3 Marathe BM, Mostafa HH, Vogel P, Pascua PNQ, Jones JC, Russell CJ, Webby RJ, Govorkova EA. A pharmacologically immunosuppressed mouse model for assessing influenza B virus pathogenicity and oseltamivir treatment. Antiviral Res 2017;148:20-31. [PMID: 29100887 DOI: 10.1016/j.antiviral.2017.10.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
4 Robertson CA, DiazGranados CA, Decker MD, Chit A, Mercer M, Greenberg DP. Fluzone® High-Dose Influenza Vaccine. Expert Rev Vaccines 2016;15:1495-505. [PMID: 27813430 DOI: 10.1080/14760584.2016.1254044] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
5 Hawkinson D, Hinthorn D, Danziger-Isakov L. Novel antiviral agents for respiratory viral infection in immunocompromised adults. Curr Infect Dis Rep 2013;15:497-503. [PMID: 24146257 DOI: 10.1007/s11908-013-0370-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
6 Trebbien R, Christiansen CB, Fischer TK. Antiviral resistance due to deletion in the neuraminidase gene and defective interfering-like viral polymerase basic 2 RNA of influenza A virus subtype H3N2. J Clin Virol 2018;102:1-6. [PMID: 29448067 DOI: 10.1016/j.jcv.2018.02.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
7 Chen L, Han X, Li YL, Zhang C, Xing X. FluA-p score: a novel prediction rule for mortality in influenza A-related pneumonia patients. Respir Res 2020;21:109. [PMID: 32384935 DOI: 10.1186/s12931-020-01379-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Trubiano JA, Chen S, Slavin MA. An Approach to a Pulmonary Infiltrate in Solid Organ Transplant Recipients. Curr Fungal Infect Rep 2015;9:144-54. [PMID: 32218881 DOI: 10.1007/s12281-015-0229-y] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
9 de St Maurice A, Halasa N. Preparing for the 2018-2019 influenza season. Pediatr Transplant 2018;22:e13272. [PMID: 30076691 DOI: 10.1111/petr.13272] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Ison MG. Influenza prevention and treatment in transplant recipients and immunocompromised hosts. Influenza Other Respir Viruses 2013;7 Suppl 3:60-6. [PMID: 24215383 DOI: 10.1111/irv.12170] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
11 L'Huillier AG, Kumar D. Immunizations in solid organ and hematopoeitic stem cell transplant patients: A comprehensive review. Hum Vaccin Immunother 2015;11:2852-63. [PMID: 26291740 DOI: 10.1080/21645515.2015.1078043] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
12 Pascua PNQ, Mostafa HH, Marathe BM, Vogel P, Russell CJ, Webby RJ, Govorkova EA. Pathogenicity and peramivir efficacy in immunocompromised murine models of influenza B virus infection. Sci Rep 2017;7:7345. [PMID: 28779075 DOI: 10.1038/s41598-017-07433-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
13 Hodinka RL. Respiratory RNA Viruses. Microbiol Spectr 2016;4. [PMID: 27726802 DOI: 10.1128/microbiolspec.DMIH2-0028-2016] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
14 Verolet CM, Posfay-Barbe KM. Live virus vaccines in transplantation: friend or foe? Curr Infect Dis Rep 2015;17:472. [PMID: 25870140 DOI: 10.1007/s11908-015-0472-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
15 Trebbien R, Pedersen SS, Vorborg K, Franck KT, Fischer TK. Development of oseltamivir and zanamivir resistance in influenza A(H1N1)pdm09 virus, Denmark, 2014. Euro Surveill 2017;22:30445. [PMID: 28128091 DOI: 10.2807/1560-7917.ES.2017.22.3.30445] [Cited by in Crossref: 33] [Cited by in F6Publishing: 9] [Article Influence: 6.6] [Reference Citation Analysis]
16 Abbas S, Raybould JE, Sastry S, de la Cruz O. Respiratory viruses in transplant recipients: more than just a cold. Clinical syndromes and infection prevention principles. Int J Infect Dis 2017;62:86-93. [PMID: 28739424 DOI: 10.1016/j.ijid.2017.07.011] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 9.4] [Reference Citation Analysis]
17 Zambon M. Developments in the treatment of severe influenza: lessons from the pandemic of 2009 and new prospects for therapy. Curr Opin Infect Dis 2014;27:560-5. [PMID: 25333476 DOI: 10.1097/QCO.0000000000000113] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
18 Pascua PNQ, Marathe BM, Vogel P, Webby RJ, Govorkova EA. Optimizing T-705 (favipiravir) treatment of severe influenza B virus infection in the immunocompromised mouse model. J Antimicrob Chemother 2019;74:1333-41. [PMID: 30715325 DOI: 10.1093/jac/dky560] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
19 Liu Y, Wang Y, Mai H, Chen Y, Liu B, Liu Y, Ji Y, Cong X, Gao Y. Clinical characteristics, risk factors and antiviral treatments of influenza in immunosuppressed inpatients in Beijing during the 2015-2020 influenza seasons. Virol J 2022;19:11. [PMID: 35033116 DOI: 10.1186/s12985-021-01739-1] [Reference Citation Analysis]
20 Ma C, Zhang J, Wang J. Pharmacological Characterization of the Spectrum of Antiviral Activity and Genetic Barrier to Drug Resistance of M2-S31N Channel Blockers. Mol Pharmacol 2016;90:188-98. [PMID: 27385729 DOI: 10.1124/mol.116.105346] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
21 Wang J, Li F, Ma C. Recent progress in designing inhibitors that target the drug-resistant M2 proton channels from the influenza A viruses. Biopolymers 2015;104:291-309. [PMID: 25663018 DOI: 10.1002/bip.22623] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 7.0] [Reference Citation Analysis]
22 Donato-Santana C, Theodoropoulos NM. Immunization of Solid Organ Transplant Candidates and Recipients: A 2018 Update. Infect Dis Clin North Am 2018;32:517-33. [PMID: 30146021 DOI: 10.1016/j.idc.2018.04.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
23 Marathe BM, Asthagiri Arunkumar G, Vogel P, Pascua PNQ, Jones J, Webby RJ, Krammer F, Govorkova EA. Monoclonal Antibody Therapy Protects Pharmacologically Immunosuppressed Mice from Lethal Infection with Influenza B Virus. Antimicrob Agents Chemother 2020;64:e00284-20. [PMID: 32631823 DOI: 10.1128/AAC.00284-20] [Reference Citation Analysis]
24 Abed Y, Boivin G. A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir. Open Forum Infect Dis 2017;4:ofx105. [PMID: 28852674 DOI: 10.1093/ofid/ofx105] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
25 Goeijenbier M, van Genderen P, Ward BJ, Wilder-Smith A, Steffen R, Osterhaus AD. Travellers and influenza: risks and prevention. J Travel Med 2017;24:taw078. [PMID: 28077609 DOI: 10.1093/jtm/taw078] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
26 de St Maurice A, Halasa N. Preparing for the 2019-2020 influenza season. Pediatr Transplant 2020;24:e13645. [PMID: 31885157 DOI: 10.1111/petr.13645] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]